Quarter Ended Sep 30, 2022
For Fiscal Year Ending December 31, 2021
Sign up today and receive company updates straight to your inbox.
Our Investor Fact Sheet provides quick-hit details about how we're improving prescription drug safety through chemistry. Quickly learn about who we are, our technology platforms, our targeted therapy areas, and more.
Ensysce Biosciences, Inc. is a clinical stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the fear of and the potential for opioid misuse, abuse and overdose. Our current development pipeline includes two new drug platforms - an abuse-resistant prodrug technology – the Trypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection prodrug technology - the Multi-Pill Abuse Resistant, or the MPAR™ platform. The TAAP platform is designed to improve the care of patients with chronic pain while reducing the human and economic costs associated with prescription opioid drug abuse. The MPAR™ platform when combined with our TAAP prodrugs is designed not only to prevent abuse of prescription drugs but also to reduce overdose occurrences. Additionally, nafamostat is an ingredient in our overdose protection combination products, is also being developed for the intended purpose of treating infection and pulmonary lung diseases.
Ensysce Biosciences, Inc.
7946 Ivanhoe Ave
La Jolla, CA 92037
MZ North America
5055 Avenida Encinas
Carlsbad, CA 92008